Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2016 Jun 1.

Published in final edited form as: Am J Ophthalmol. 2015 Feb 19;159(6):1027–1035.e3. doi: 10.1016/j.ajo.2015.02.008

Galectin-3 is partially degraded in tears of dry eye patients. (Upper panel) Schematic diagram illustrating the MMP-mediated cleavage of galectin-3 at the Ala₆₂-Tyr₆₃ bond in the N-terminus to produce a 22 kDa cleavage product lacking the multimerization domain (galectin-3C). (Lower left) By immunoblot, a partially degraded form of galectin-3 with a molecular weight of 25.4 kDa is detected in tears of patients with dry eye. (Lower right) Densitometric analyses revealed a significant increase in the ratio between galectin-3C and galectin-3 in tears of dry eye patients compared to tears of healthy subjects. Data for individual samples are presented. PGR, proline, glycine, and tyrosine-rich domain; CRD, carbohydrate recognition domain; N-term, N-terminus; aa, amino acid. *P < .05.

Galectin-3 is partially degraded in tears of dry eye patients. (Upper panel) Schematic diagram illustrating the MMP-mediated cleavage of galectin-3 at the Ala₆₂-Tyr₆₃ bond in the N-terminus to produce a 22 kDa cleavage product lacking the multimerization domain (galectin-3C). (Lower left) By immunoblot, a partially degraded form of galectin-3 with a molecular weight of 25.4 kDa is detected in tears of patients with dry eye. (Lower right) Densitometric analyses revealed a significant increase in the ratio between galectin-3C and galectin-3 in tears of dry eye patients compared to tears of healthy subjects. Data for individual samples are presented. PGR, proline, glycine, and tyrosine-rich domain; CRD, carbohydrate recognition domain; N-term, N-terminus; aa, amino acid. *P < .05.